Would having a better understanding of what payers expect when evaluating the value of an orphan drug be of benefit for you? Would the opportunity to gain insight into the minds of reimbursement authorities across Europe assist you when negotiating prices for your orphan product? Do you know what needs to be displayed by orphan drug developers to demonstrate added value of their product to payers?
In times of economic scrutiny, it is essential to gain whatever advantage is available to ensure the market positioning strategy and reimbursement considerations are tackled early in drug development. This year in 2012, the World Orphan Drug Congress has a dedicated pricing, reimbursement and market access track to stage real life case studies and provide tangible solutions to the final hurdle in drug development. You won't just be able to learn and hear from your leading industry colleagues who are successfully posting high revenue numbers for their approved orphan drugs, as we have also confirmed several reimbursement authorities across Europe to add their weight to the debate.
Ri De Ridder, Director General of the Healthcare Department at the National Institute for Health & Disability Insurance (Belgium) will be one of this year's thought leaders and will present on "why transparency between stakeholders is essential when discussing pricing & reimbursement". I was also fortunate the pose a few questions that delve deeper and further open up the the pricing, reimbursement and market access debate. I would like to take this chance to thank Ri De Ridder for his opinions below:
What are the major challenges impeding or slowing the access of orphan drugs to patients in need? – The uncertainty about cost-effectiveness at the point of reimbursement decision in the context of high prices/high cost calls for other mechanisms of pricing and reimbursing in which fair risk sharing and lifecycle approaches are highly needed.
What needs to be displayed by orphan drug developers to demonstrate added value of their product to payers? – Much earlier involvement of payers through systems like early dialogue, early access schemes, agreed post marketing follow-up connected with reimbursement adjustment, integrated financing models (including cost of drug treatment in global cost).
What are the foreseeable game changers set to influence pricing levels and reimbursement attitudes? – The new patient mobility directive has given an important push for more European collaboration on rare diseases (cfr EUCERD), together with the Council recommendation on rare diseases, the political process of European collaboration is strongly launched.
Agree or disagree? Comments are always welcome below.
You can DOWNLOAD THE FREE BROCHURE now for the 2012 World Orphan Drug Congress and in order to confirm your position within this thought leading forum, register here before 7th September 2012 for the best early bird rate.
Other blogs of interest may be "Challenges of partnering in the rare disease industry" or "Are HTA & payment decisions impeding access to rare disease therapies?"
For more updates on pharma, biotech and R&D, follow us on Twitter: @biopharmaevents or join our LinkedIn group: BioPharma- Networking for Pharmaceuticals, Biotech and R&D